Genetic Engineering

Biotech stocks remain highly volatile, influenced by FDA trial results and interest rate changes. The pandemic spotlighted biotech, leading to increased public-private collaborations. Recent market conditions hint at growth, with strategic mergers and novel therapies gaining attention. Central banks’ rate cuts enhance